
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Anxiety disorders cause much misery and disability in children and adolescents. Psychotherapy and recent advances in drug treatment offer the best hope of improving patients & lives.






